|
Aug 26
|
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
|
|
Aug 9
|
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
|
|
Jul 24
|
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
|
|
Jul 24
|
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
|
|
Jun 25
|
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
|
|
Jan 9
|
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
|
|
Dec 8
|
Skye Bioscience Responds to OTC Markets Promotional Policy
|
|
Dec 5
|
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
|
|
Nov 28
|
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
|
|
Aug 21
|
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
|
|
Jul 6
|
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
|